Induction of cementogenesis by recombinant human osteogenic protein-1 (hop-1/bmp-7) in the baboon (Papio ursinus).
Recombinant human osteogenic protein-1 (hOP-1), a member of the bone morphogenetic protein family, was examined for its efficacy in periodontal regeneration. Twelve furcation defects, surgically prepared in the first and second mandibular molars, were treated with bovine insoluble collagenous matrix in conjunction with 0.0 (control), 100 and 500 mu g of recombinant hOP-1 per g of matrix. After 60 days of healing, histological and histometric analyses on serial, undemineralized sections cut at 7 mu m showed substantial cementogenesis on the exposed dentine of furcations treated with both doses of hOP-1 (p < 0.01 vs control). Foci of nascent mineralization were seen within the newly deposited cementoid along the coronal areas of hOP-1-treated defects. Within the furcations, there were substantial amounts of residual collagenous carrier, interspersed with a mineralized matrix having histological features of cementum. This mineralized cementum-like material was predominantly deposited around the carrier, and blended into newly formed cementum along the root surfaces. In the apical area, the cementum-like material and the remaining alveolar bony housing were not connected; indeed the two components were separated by a fibrovascular tissue that had numerous features of the periodontal ligament space. Formation and insertion of Sharpey's fibres into newly formed root cementum were also observed. It is likely that the expression of specific cell phenotypes by hOP-1 is regulated, in part, by the extracellular matrix microenvironment, including dentine. Thus, exposed dentine, in the presence of exogenous hOP-1 at the doses tested, may preferentially modulate the expression of the cementogenic phenotype. These findings in a non-human primate show that hOP-1, at the doses tested, induced cementogenesis on surgically denuded root surfaces, indicating a specific function during repair and regeneration of periodontal tissues.
Ripamonti
U
U
Bone Research Laboratory, Medical Research Council/University of the Witwatersrand, Johannesburg, South Africa.
Heliotis
M
M
Rueger
D C
DC
Sampath
T K
TK
D000539:Alveolar Process / Q000187:drug effects / Q000473:pathology; D000818:Animals; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000494:pharmacology*; D002417:Cattle; D003094:Collagen / Q000627:therapeutic use; D003739:Dental Cementum / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D003804:Dentin / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D005109:Extracellular Matrix / Q000502:physiology; D017823:Furcation Defects / Q000188:drug therapy / Q000473:pathology; D005786:Gene Expression Regulation; D006801:Humans; D010215:Papio; D010513:Periodontal Ligament / Q000187:drug effects / Q000473:pathology; D010519:Periodontium / Q000187:drug effects / Q000473:pathology; D010641:Phenotype; D011994:Recombinant Proteins; D012038:Regeneration / Q000187:drug effects; D014074:Tooth Calcification / Q000187:drug effects; D014092:Tooth Root / Q000187:drug effects / Q000473:pathology; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000494:pharmacology*; D014945:Wound Healing
C525819:BMP7 protein, human; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D003094:Collagen